Abstract
Objective To study and explore the clinical effect of imatinib mesylate in the treatment of chronic myeloid leukemia. Methods From January 2013 to January 2017, 60 patients with chronic myeloid leukemia in the Second Hospital of Jiaxing were included in the study.The patients were randomly divided into control group and observation group, with 30 cases in each group.The control group was given routine chemotherapy, the observation group was given routine chemotherapy combined wth imatinib mesylate orally.After 6 months of treatment, the clinical curative effect, the incidence of adverse reactions, immune function, quality of life score of the two groups were compared. Results The response rate of the observation group was 76.67%(23/30), which was higher than 50.00%(15/30) of the control group (χ2=4.593, P 0.05). After treatment, the indicators of immune function in the observation group were higher than those in the control group(t=4.482, 3.731, 3.361, all P<0.05). After treatment, the quality of life scores in the observation group were higher than those in the control group(t=8.898, 5.945, 9.309, 5.679, all P<0.05). Conclusion Imatinib mesylate in the treatment of patients with chronic myelogenous leukemia can effectively improve the efficacy and safety of chemotherapy, reduce the effect of chemotherapy on the immune function of patients, improve their quality of life. Key words: Leukemia, myelogenous, chronic; Inatinib; Immune; Quality of life
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
